REGENERON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
REGENERON PHARMACEUTICALS, INC. (REGN) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $133.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $133.30M.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2013 was $34.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $133.30M 10-K · filed 2026-02-04 |
| 2013-12-31 | $34.00M 10-K · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |